Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRP Plus Topical Insulin for Post-Inflammatory Anosmia
NCT07383415Not yet recruiting
- Start
- Mar 2026
- Primary completion
- Dec 2026
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Randomised trial of Generex Oral-lyn in anosmia (2 arms). Primary endpoint: Change in Olfactory Function at 12 months. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
Generex Oral-lyn
03
Conditions
anosmia
Beyond the preview
Go deeper on NCT07383415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07383415.